More recently, it has been reported that immunotherapies based on IL-6 [98] or IL-17 [16] may be more efficacious for RA [2,99] than the original TNF-α antagonists exemplified by Adalimumab (Humira®) [100,101], Etanercept (Enbrel®) [102,103], or Infliximab (Remicade®) [102,103,104,105,106]. This evidence concerns the gene IL6 and rheumatoid arthritis.